| review article | Q7318358 |
| scholarly article | Q13442814 |
| editorial | Q871232 |
| P2093 | author name string | Mohammed Shawkat Razzaque | |
| P2860 | cites work | Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 | Q24290481 |
| FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis | Q24319751 | ||
| Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia | Q24623628 | ||
| Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members | Q24683254 | ||
| Role of fibroblast growth factor 23 in health and in chronic kidney disease | Q28254210 | ||
| Fibroblast growth factor 23: roles in health and disease | Q28262842 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo | Q28572995 | ||
| Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis | Q33932297 | ||
| Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers | Q33974129 | ||
| Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
| Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. | Q34702230 | ||
| Cellular and molecular events leading to renal tubulointerstitial fibrosis. | Q34786418 | ||
| A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis | Q35925637 | ||
| FGF23 and disorders of phosphate homeostasis | Q36111415 | ||
| Structural and biochemical properties of fibroblast growth factor 23. | Q36216956 | ||
| Hypophosphatemia: an update on its etiology and treatment | Q36272304 | ||
| Phosphatonins and the regulation of phosphate homeostasis | Q36604351 | ||
| Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization | Q36848109 | ||
| The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis | Q36860289 | ||
| Does renal ageing affect survival? | Q36896257 | ||
| New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. | Q36905432 | ||
| Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism? | Q36966608 | ||
| In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis | Q37072412 | ||
| Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? | Q37182735 | ||
| Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23 | Q37418420 | ||
| Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. | Q40447584 | ||
| An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. | Q40482177 | ||
| Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders | Q40530218 | ||
| Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process | Q42736434 | ||
| Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis | Q44779387 | ||
| Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression | Q44810019 | ||
| FGF-23 in patients with end-stage renal disease on hemodialysis | Q44846350 | ||
| Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. | Q45197408 | ||
| Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. | Q46680438 | ||
| Severely reduced production of klotho in human chronic renal failure kidney | Q49064415 | ||
| Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 | ||
| FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. | Q54733425 | ||
| Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice | Q56767950 | ||
| Association of Disorders in Mineral Metabolism with Progression of Chronic Kidney Disease | Q57772116 | ||
| The collagen-specific molecular chaperone HSP47: is there a role in fibrosis? | Q79433884 | ||
| FGF-23, vitamin D and calcification: the unholy triad | Q80394650 | ||
| Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism | Q81853118 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4-7 | |
| P577 | publication date | 2008-11-07 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Does FGF23 toxicity influence the outcome of chronic kidney disease? | |
| P478 | volume | 24 |
| Q38057137 | Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? |
| Q37244863 | Can features of phosphate toxicity appear in normophosphatemia? |
| Q38025185 | Cardiovascular disease in chronic kidney disease: untying the Gordian knot |
| Q85799725 | Circulating Klotho levels: clinical relevance and relationship with tissue Klotho expression |
| Q34989319 | Clinical Significance of FGF-23 in Patients with CKD. |
| Q37641052 | Clinical relevance of FGF-23 in chronic kidney disease |
| Q52743002 | Dietary phosphate modifies lifespan in Drosophila. |
| Q28085476 | Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity |
| Q64970703 | Endocrine regulation of MFS2 by branchless controls phosphate excretion and stone formation in Drosophila renal tubules. |
| Q39866881 | FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment |
| Q42878661 | FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism |
| Q43074642 | FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6. |
| Q24653541 | FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? |
| Q84083027 | Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease |
| Q33904467 | Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease? |
| Q46567248 | Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients |
| Q35967107 | Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease |
| Q38076051 | From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease. |
| Q34631633 | Genetic determinants of phosphate response in Drosophila |
| Q92669192 | Identification of a p.Trp403* nonsense variant in PHEX causing X-linked hypophosphatemia by inhibiting p38 MAPK signaling |
| Q41460824 | Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. |
| Q33572351 | In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels |
| Q37415834 | Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model |
| Q35059924 | Molecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho system |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q38049170 | Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate |
| Q34690795 | Phosphate sensing |
| Q35059905 | Phosphate toxicity: new insights into an old problem |
| Q53149178 | Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease. |
| Q35126790 | Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase |
| Q34168361 | Roles of major facilitator superfamily transporters in phosphate response in Drosophila |
| Q36933339 | The FGF family: biology, pathophysiology and therapy |
| Q24625902 | The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis |
| Q36992839 | The role of Klotho in energy metabolism |
| Q42529430 | Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372 |
| Q58104395 | Thymic Epithelial Cell Support of Thymopoiesis Does Not Require |
| Q37221997 | Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function |
| Q37919185 | Vitamin D and immune function: an overview |
| Q39812781 | αKlotho and Chronic Kidney Disease |
Search more.